Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma

Cheng, Qianwen; Zhao, Fei; Zhang, Bo; Zhang, Yuyang; Cai, Li; Qiao, Bing; Hu, Yu; Sun, Chaoyang

doi:10.1016/j.intimp.2021.108016

Cited by 7 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abe et al, Cheng et al and Zhang et al have also reported similar area under the ROC curve or C-index between ISS and R-ISS. 19,[28][29][30] We have shown that whatever the performance measures, there was no significant improvement in patient discrimination and classification using ISS, R-ISS or its modification by subdivision of the stage II category, suggesting that a better performance measure could only be reached using other biomarkers than those used by R-ISS. The better stratification of the R-ISS stage II subgroup according to the presence of high-risk CA was also described by the Mayo clinic but an ISS effect was not reported or maybe was not investigated in this study due to the small sample size of their retrospective cohort.…”

Section: Discussionmentioning

confidence: 84%

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Schavgoulidze¹,

Lauwers‐Cancès²,

Perrot³

et al. 2022

haematol

View full text Add to dashboard Cite

In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately defined. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to identify high-risk patients. The main purpose of our work was to explore the heterogeneity of outcome among R-ISS stage II patients assessing the impact of ISS, chromosomal abnormalities (CA) and LDH level in this subgroup. Data were issued from 1,343 newly diagnosed myeloma patients up to 65 years, enrolled in 3 clinical trials implemented by the Intergroupe Francophone du Myelome. All patients were eligible to an intensive treatment. Patients R-ISS stage II but ISS stage I had 1.6 times more risk of death than patients R-ISS stage I (adjusted HR 1.6; 95% CI, 1.1 to 2.2; P = .01) and patients R-ISS stage II but ISS stage III had a better overall survival than patients R-ISS stage III (adjusted HR 0.7; 95% CI, 0.4 to 0.9, P = .02). However, among patients classified in R-ISS II, ISS stage and CA (del(17p) and t(4;14)) were still relevant prognostic factors for death. Dividing R-ISS stage II into 3 subgroups: ISS I with standard risk CA, ISS II or III with standard risk CA and, high risk CA patients, median overall survivals were respectively not reached, 112 and 71 months (P < 0.001). In conclusion, stratification of patients in the R-ISS stage II group can be improved by taking into account CA and ISS. However, this does not improve predictive performance of survival models.

show abstract

Section: Discussionmentioning

confidence: 84%

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Schavgoulidze¹,

Lauwers‐Cancès²,

Perrot³

et al. 2022

haematol

View full text Add to dashboard Cite

show abstract

“…Actually, the reduction in albumin levels is due to the fact that interleukin-6 (IL-6), but above all the altered cytokine network present in MM, reduces the hepatic synthesis of albumin, approximately equal to 200 mg per kilogram of body weight per day [ 34 , 35 , 36 ]. Even if in most recent nomograms related to the prognostic stratification of these patients’ cytokines are not taken into account [ 37 , 38 ], other authors have included the cytokines in prognostic nomograms, in particular, for newly diagnosed MM patients [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors

et al. 2023

View full text Add to dashboard Cite

Background: In this single center study, we retrospectively evaluated the calculated hemorheological profile in patients with a new diagnosis of multiple myeloma, with the aim to evaluate possible relationships with some prognostic predictors, such as ISS, albumin levels, beta2-microglobulin, red cell distribution width, and bone marrow plasma cell infiltration. Methods: In a cohort of 190 patients, we examined the calculated blood viscosity using the de Simone formula, and the albumin/fibrinogen ratio as a surrogate of erythrocyte aggregation, and then we related these parameters to prognostic factors, using the Kruskal–Wallis and the Mann–Whitney tests, respectively. Results: From our analysis, it emerged that the evaluated hemorheological pattern differed in the three isotypes of multiple myeloma, and the whole blood viscosity was higher in IgA and IgG isotypes with respect to the light chain multiple myeloma (p < 0.001). Moreover, we observed that, as the ISS stage progressed, the albumin/fibrinogen ratio was reduced, and the same hemorheological trend was traced in subgroups with lower albumin levels, higher beta2-microglobulin and red cell distribution width RDW values, and in the presence of a greater bone marrow plasma cell infiltrate. Conclusions: Through the changes in blood viscosity in relation to different prognostic factors, this analysis might underline the role of the hemorheological pattern in multiple myeloma.

show abstract

“…Cheng et al constructed a nomogram for predicting OS and progression-free survival, which included circulating plasma cells as an independent prognostic factor. Another nomogram proposed by Cheng et al incorporated cytokine MIP-1α as a novel indicator ( 28 , 29 ). These two nomograms have several common limitations, such as single-center retrospective data, a small sample size, and short follow-up durations.…”

Section: Discussionmentioning

confidence: 99%

Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification

Zuo

Sun

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThis study aimed to develop reliable nomogram-based predictive models that could guide prognostic stratification and individualized treatments in patients with multiple myeloma (MM).MethodsClinical information of 560 patients was extracted from the MM dataset of the MicroArray Quality Control (MAQC)-II project. The patients were divided into a development cohort (n = 350) and an internal validation cohort (n = 210) according to the therapeutic regimens received. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for nomogram construction. Nomogram performance was assessed using concordance indices, the area under the curve, calibration curves, and decision curve analysis. The nomograms were also validated in an external cohort of 56 patients newly diagnosed with MM at Nanjing Drum Tower Hospital from May 2016 to June 2019.ResultsLactate dehydrogenase (LDH), albumin, and cytogenetic abnormalities were incorporated into the nomogram to predict overall survival (OS), whereas LDH, β2-microglobulin, and cytogenetic abnormalities were incorporated into the nomogram to predict event-free survival (EFS). The nomograms showed good predictive performances in the development, internal validation, and external validation cohorts. Additionally, we observed a superior prognostic predictive ability in nomograms compared to that of the International Staging System. According to the prognostic nomograms, risk stratification was applied to divide the patients into two risk groups. The OS and EFS rates of low-risk patients were significantly better than those of high-risk patients, suggesting a greater function of the nomogram models for risk stratification.ConclusionTwo simple-to-use prognostic models were established and validated. The proposed nomograms have potential clinical applications in predicting OS and EFS for patients with MM.

show abstract

Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma

Cited by 7 publications

References 43 publications

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors

Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification

Contact Info

Product

Resources

About